Transcriptomic and Epigenomics Analysis for the identification of biomarkers involved in the drug resistance mechanisms of Multiple Myeloma.
Project objectivesThe project aims to characterize transcriptional and epigenetic differences, including miRNAs, between MM tumor cells sensitive and resistant to conventional therapies. The identification and characterization of SE elements in myeloma plasma cells, with subsequent analysis of the transcriptional factors associated with them, could be important to clarify the mechanisms that regulate tumor progression and acquired resistance phenomena in MM. The ultimate goal is to identify new prognostic and predictive biomarkers that can be exploited from a therapeutic point of view to increase the clinical success of targeted therapies. |
Start and end date |
May 25, 2021 |
Project Manager |
Ombretta Annibali - Principal Investigator |
Coordinating institution of the project |
IFO-IRE, Rome |
Other Institutions involved |
|